News

The company claims that its drug response marker has pioneered a method of identifying cancer cell response and sensitivity to various chemotherapeutic and biologic agents at the biopsy

The phase I study titled, ‘A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in

Abstral, developed by Orexo is a new, rapidly disintegrating, sublingual formulation of fentanyl, a long-established opioid used for the management of episodes of breakthrough pain experienced by cancer

For Q4 2009, Pfizer posted net income of $767m, an increase of 188% compared to $266m in the prior-year quarter, and reported diluted EPS of $0.10, an increase

Mr Fauchet has joined GSK from Sanofi Aventis where he worked as senior vice president for business development. He joined Sanofi in 1996, and headed up the Eastern

The company had completed the 96 week dosing for the phase IIb trials in 2008, which demonstrated that after dosing, patients with HIV levels below detectable was over

Both the companies are negotiating an exclusive worldwide license that would result in Cannasat assuming product development and commercialisation rights to APL-130277 from Adagio in return for development

The study was conducted in approximately 100 clinical sites throughout North America and Europe. The company plans to use data from the study to support submission of a

The candidate is produced through a proprietary process using a new growth environment that promotes faster maturation than chicken eggs, the standard environment since 1943. The phase II